granisetron 2mg tablets
apc pharmaceuticals & chemicals (europe) ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
alliance healthcare (distribution) ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
sigma pharmaceuticals plc - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
cubic pharmaceuticals ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
colorama pharmaceuticals ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
ennogen healthcare ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 2mg tablets
j m mcgill ltd - granisetron hydrochloride - oral tablet - 2mg
granisetron 1mg tablets
torrent pharma (uk) ltd - granisetron hydrochloride - oral tablet - 1mg
irinotecan hydrochloide injection irinotecan hydrochloride injection
gland pharma limited - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - • irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-fu) and leucovorin (lv) for patients with metastatic carcinoma of the colon or rectum. • irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. • irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. risk summary based on findings from animal studies and its mechanism of action, irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)]. available postmarketing and published data reporting the use of irinotecan hydrochloride injection in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscar
irinotecan hydrochloide injection irinotecan hydrochloride injection
xiromed llc - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - - irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-fu) and leucovorin (lv) for patients with metastatic carcinoma of the colon or rectum. - irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. • irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. risk summary based on findings from animal studies and its mechanism of action, irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)]. available postmarketing and published data reporting the use of irinotecan hydrochloride injection in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarri